http://www.cancernetwork.com Cancer Screening, Diagnosis, Treatment, Prevention - Practical Reviews & Free CME - Cancer Network en Copyright 2009, CMPMedica US Sat, 11 Feb 2012 08:30:02 GMT Sat, 11 Feb 2012 08:30:02 GMT http://blogs.law.harvard.edu/tech/rss http://www.cancernetwork.com/hematologic-malignancies/content/article/10165/2028729?CID=rss In the current issue of ONCOLOGY, Gertz and Dispenzieri provide a scholarly review of the early recognition, diagnosis, and treatment of immunoglobulin light-chain (AL) amyloidosis. Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/ovarian-cancer/content/article/10165/2028709?CID=rss Ovarian cancers account for more than 50% of gynecologic cancer deaths. This is attributable to the late stage of the disease at diagnosis. Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/ovarian-cancer/content/article/10165/2028694?CID=rss The development of poly(ADP-ribose) polymerase (PARP) inhibitors as a new class of anticancer agents has created a tremendous amount of hope in the ovarian cancer community, especially in the high-risk, difficult-to-screen, hereditary ovarian cancer population. Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/colorectal-cancer/content/article/10165/2030129?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2030122&t=1328809106313" align="left" style="margin-right:5px; margin-top:2px"/>In this interview, Dr. David Ahlquist, gastroenterologist and professor of medicine at the Mayo Clinic in Rochester in Minnesota, discusses early detection methods of colorectal cancer, touching on sigmoidoscopy, colonoscopies, fecal blood testing, and in particular, stool DNA screening.<br style="clear:both;"/> Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/lung-cancer/content/article/10165/2028754?CID=rss Screening is always an issue that generates a great deal of emotion, as recently seen with the controversies surrounding mammography and prostate-specific antigen (PSA) testing. Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/lung-cancer/content/article/10165/2028749?CID=rss Tanner et al provide a concise review of lung cancer screening, including discussion of past failed attempts, the success of the National Lung Screening Trial (NLST), and promising new avenues for improving on the NLST results. Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/lung-cancer/content/article/10165/2028739?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=1747625&t=1328807902190" border="0" align="left" height="50" width="50" style="padding-right:5px; padding-top:2px; padding-bottom:2px"/>In this review, the authors discuss past attempts at lung cancer screening, the results of the National Lung Cancer Screening Trial, and innovative tests for lung cancer screening currently being evaluated.<br style="clear:both;"/> Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/hematologic-malignancies/content/article/10165/2028724?CID=rss Immunoglobulin light chain (AL) amyloidosis develops in 2% of individuals with monoclonal plasma cell dyscrasias. In this issue of ONCOLOGY, Drs. Gertz and Dispenzieri discuss AL amyloidosis, highlighting progress in the field along with outstanding challenges. Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/hematologic-malignancies/content/article/10165/2028719?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2030113&t=1328806399031" border="0" align="left" height="50" width="50" style="padding-right:5px; padding-top:2px; padding-bottom:2px"/>When light-chain amyloidosis is diagnosed prior to the development of advanced cardiomyopathy, systemic therapy is capable of producing hematologic responses that will translate into organ responses and prolonged survival.<br style="clear:both;"/> Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/ovarian-cancer/content/article/10165/2028689?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2029894&t=1328804251485" border="0" align="left" height="50" width="50" style="padding-right:5px; padding-top:2px; padding-bottom:2px"/>This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.<br style="clear:both;"/> Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/leukemia-lymphoma/content/article/10165/2028774?CID=rss The article by Thieblemont and colleagues very nicely summarizes the key pathogenetic and diagnostic features and present treatment of splenic marginal zone lymphoma (SMZL). Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/leukemia-lymphoma/content/article/10165/2028769?CID=rss Splenic lymphomas are a diverse group of lymphoid malignancies that have clinical behavior ranging from indolent to aggressive and that have both B-cell and T-cell histologies. Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/leukemia-lymphoma/content/article/10165/2028759?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2029840&t=1328798732942" border="0" align="left" height="50" width="50" style="padding-right:5px; padding-top:2px; padding-bottom:2px"/>In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic marginal zone lymphoma. <br style="clear:both;"/> Thu, 9 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/gastrointestinal-stromal-tumor/content/article/10165/2028035?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2028033&t=1328561202226" align="left" style="margin-right:5px; margin-top:2px"/>The FDA has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors in adult patients. This comes after results from a phase III trial showed that patients taking imatinib for 36 months had a 5-year overall survival of 92%, compared to 82% for those patients who took the drug for the standard 12 months of treatment.<br style="clear:both;"/> Mon, 6 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/prostate-cancer/content/article/10165/2027790?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2027922&t=1328552691461" align="left" style="margin-right:5px; margin-top:2px"/>Initial results of a multicenter trial show that 2 biomarkers, PCA3 and T2-ERG, are found at high levels in prostate cancer compared to noncancerous prostate cells and correlate well with 2 indicators of aggressive prostate cancer, tumor volume and Gleason score.<br style="clear:both;"/> Mon, 6 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/image-iq/derm/content/article/10165/2027753?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2027760&t=1328546868906" align="left" style="margin-right:5px; margin-top:2px"/>A 68-year-old woman presented with a mass on the scalp which had been present for approximately 7 years. An incisional biopsy of the scalp mass and excisional biopsy of the lymph node both revealed basal cell carcinoma, micronodular histologic subtype.<br style="clear:both;"/> Mon, 6 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/kidney-cancer/content/article/10165/2026106?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2026419&t=1328221471031" align="left" style="margin-right:5px; margin-top:2px"/>CancerNetwork speaks with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments, and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium.<br style="clear:both;"/> Fri, 3 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/prostate-cancer/content/article/10165/2024765?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2024776&t=1328048034757" align="left" style="margin-right:5px; margin-top:2px"/>It is still difficult to gauge the probability that a low-risk prostate cancer patient may be upgraded to a higher prostate cancer stage. Researchers at Vanderbilt University Medical Center have now determined that smaller prostates were more likely to evolve into more serious, aggressive disease.<br style="clear:both;"/> Wed, 1 Feb 2012 12:00:00 GMT http://www.cancernetwork.com/melanoma-skin-cancer/content/article/10165/2024253?CID=rss <img src="http://www.cancernetwork.com/image/image_gallery?img_id=2024215&t=1327957082754" align="left" style="margin-right:5px; margin-top:2px"/>The US Food and Drug Administration (FDA) announced the approval of vismodegib (Erivedge), for the treatment of advanced basal cell carcinoma, the most common type of skin cancer, for patients who are not eligible for surgery or radiation, and for metastatic disease.<br style="clear:both;"/> Tue, 31 Jan 2012 12:00:00 GMT